SUNNYVALE, Calif.–(BUSINESS WIRE)–Phase 3 trial data showed that IBI-10090 is highly effective in treating inflammation post cataract surgery.
Author: Business Wire
Meeting the Needs of Ophthalmologists: ZEISS Showcases Integrated Solutions that Deliver Faster Practice and Surgical Workflow and Address Critical Diagnostic Challenges
SAN DIEGO & DUBLIN, Calif. & JENA, Germany–(BUSINESS WIRE)–Meeting the Needs of Ophthalmologists: at ASCRS 2015, ZEISS Showcases Integrated Solutions that Deliver Faster Practice and Surgical Workflow and Address Critical Diagnostic Challenges
Modernizing Medicine Showcases New Mobile EMA Ophthalmology EMR System at the American Society of Cataract & Refractive Surgery Annual Symposium 2015
BOCA RATON, Fla.–(BUSINESS WIRE)–Modernizing Medicine the creator of the Electronic Medical Assistant® (EMA™) will showcase the latest advancements with EMA Ophthalmology® at this year’s ASCRS annual symposium.
Ivantis Completes Enrollment in Pivotal HYDRUS IV Glaucoma Study of the Hydrus™ Microstent
IRVINE, Calif.–(BUSINESS WIRE)–Ivantis Completes Enrollment in Pivotal HYDRUS IV Glaucoma Study of the Hydrus™ Microstent; Clinical Milestone is Major Step Forward to FDA Review of Innovative and Less Invasive Glaucoma Technology
Clarity Medical’s RetCam Will Be Used in a Worldwide Clinical Study for the Treatment of Premature Infant Ocular Disease
PLEASANTON, Calif.–(BUSINESS WIRE)–Clarity Medical Systems, Inc., a developer and marketer of ophthalmic diagnostic imaging technologies, is pleased to announce that their product, RetCam, will be utilized to image premature infant eyes in a study to evaluate a potential new method for treating Retinopathy of Prematurity (ROP) using Lucentis™ (ranibizumab). “The use of RetCam in a study of this medical significance demonstrates the growing worldwide acceptance of RetCam for pediatric retinal
Visioneering Technologies, Inc., Introduces NaturalVue™ 1 Day Multifocal Contact Lens Works with the Brain to Optimize Vision
ALPHARETTA, Ga.–(BUSINESS WIRE)–Visioneering Technologies, Inc. (VTI), based in Alpharetta, GA, has announced the launch of NaturalVue™ Multifocal 1 Day daily disposable contact lens that solves the needs of those with presbyopia.
pSivida VP of Research to Discuss Company’s Protein and Antibody Sustained Delivery System at 5th Ocular Diseases and Drug Development Conference
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida VP of Research to discuss company’s protein and antibody sustained delivery system at upcoming Ocular diseases and drug conference
Customer Survey Shows High Satisfaction Rate with ReVision Optics’ Near Vision Inlay for Presbyopia
LAKE FOREST, Calif.–(BUSINESS WIRE)–ReVision Optics®, Inc. (RVO), a leader in implantable inlay technology to treat presbyopia, reported a high level of satisfaction from a group of 58 patients treated for presbyopia at the Ultralase Clinics in the …
Sprint Launches Code Factory Mobile Accessibility Application for Free to Android Users Who Are Blind or Have Low Vision
SAN DIEGO–(BUSINESS WIRE)–Free app is now available, making Android smartphones more accessible for postpaid and no-contract Sprint customers
pSivida Corp. Announces Positive Outcome to European Decentralized Procedure for Approval of ILUVIEN® for the Treatment of Chronic Diabetic Macular Edema
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida announces positive outcome to European Decentralized procedure for approval for ILUVIEN for treatment of chronic diabetic macular edema
OptiMedica Begins U.S. Shipments of the Catalys™ Precision Laser System; First U.S. Patients Treated at Mann Eye Institute, Houston
SANTA CLARA, Calif.–(BUSINESS WIRE)–OptiMedica begins shipping the Catalys Precision Laser System for cataract surgery in the U.S. First U.S. patients have been treated at Mann Eye Institute in Houston.
Status of Strategic Partnership Discussions Related to RGN-259 Ophthalmic Eye Drop
ROCKVILLE, Md.–(BUSINESS WIRE)–RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) is updating stockholders on the status of strategic discussions related to its ophthalmic drug candidate, RGN-259. Since…
pSivida Corp. to Hold Monday November 14 Conference Call to Discuss Complete Response Letter for ILUVIEN® for DME and pSivida’s Product Pipeline
WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida to hold conference call Monday to discuss product pipeline and CRL from FDA for ILUVIEN
OPKO Announces Sale of Ophthalmic Instrumentation Business
MIAMI–(BUSINESS WIRE)–OPKO Health, Inc. (NYSE: OPK) has agreed to sell its ophthalmic instrumentation business to OPTOS, Inc., a subsidiary of Optos plc, a leading and rapidly growing medical technology company engaged in the design, development, man…
AGTC Receives Grant from the Foundation Fighting Blindness for Pre-Clinical Study of Gene Therapy for Eye Disease
GAINESVILLE, Fla.–(BUSINESS WIRE)–AGTC receives significant grant funding from the Foundation Fighting Blindness to develop treatment for genetic eye disease, XLRS, causing blindness in young boys.
Acucela and Otsuka Pharmaceutical Announce the Initiation of a Phase 1/2 Clinical Trial for OPA-6566 in Patients with Open-angle Glaucoma or Ocular Hypertension
SEATTLE & TOKYO–(BUSINESS WIRE)–Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, and Otsuka Pharmaceutical Co., Ltd., today announced the initiation of a Phase 1/2 clinical trial for…
EyeMed Vision Care Expands Member Wellness Focus with Diabetic Eye Care Benefit
MASON, Ohio–(BUSINESS WIRE)–EyeMed Vision Care introduces a new Diabetic Eye Care benefit that provides follow-up care and supplementary diagnostic testing for patients with diabetes, a leading cause of adult blindness. Full Story →
Neurotech’s NT-501 Implant Slows Vision Loss in Patients with Geographic Atrophy Associated with Dry AMD as Reported in PNAS
LINCOLN, R.I.–(BUSINESS WIRE)–Neurotech announced that it was reported in PNAS that its product candidate NT-501 slowed progression of vision loss in patients with geographic atrophy associated with dry AMD in a Phase 2 study. Full Story →
Lucentis Phase III Study Meets Primary Endpoint for Improving Vision in Patients With Diabetic Macular Edema (DME)
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that one of two Phase III studies evaluating monthly Lucentis® (ranibizumab injection) in patients with diabetic m…
Alcon Posts Solid Fourth Quarter Financial Results
HUENENBERG, Switzerland–(BUSINESS WIRE)–Alcon, Inc. (NYSE:ACL) reported that global sales rose 5.7 percent to $1.81 billion for the fourth quarter of 2010. Revenue from acquisitions added 100 basis points to sales growth in the quarter, while foreign…